Neurocrine Biosciences (NBIX) Short Interest Ratio & Short Volume $117.44 -5.44 (-4.43%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Neurocrine Biosciences Short Interest DataNeurocrine Biosciences (NBIX) has a short interest of 2.48 million shares. This marks a -5.34% decrease in short interest from the previous month. The short interest ratio (days to cover) is 2.6, indicating that it would take 2.6 days of the average trading volume of 997,520 shares to cover all short positions.Current Short Interest2,480,000 sharesPrevious Short Interest2,620,000 sharesChange Vs. Previous Month-5.34%Dollar Volume Sold Short$298.27 millionShort Interest Ratio2.6 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares101,250,000 sharesPercentage of Shares Shorted2.45%Today's Trading Volume1,255,345 sharesAverage Trading Volume997,520 sharesToday's Volume Vs. Average126% Short Selling Neurocrine Biosciences? Sign up to receive the latest short interest report for Neurocrine Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNBIX Short Interest Over TimeNBIX Days to Cover Over TimeNBIX Percentage of Float Shorted Over Time Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Neurocrine Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20242,480,000 shares $298.27 million -5.3%N/A2.6 $120.27 10/15/20242,620,000 shares $307.43 million +6.9%N/A2.8 $117.34 9/30/20242,450,000 shares $282.29 million +9.9%N/A2.7 $115.22 9/15/20242,230,000 shares $272.62 million +4.2%N/A2.5 $122.25 8/31/20242,140,000 shares $271.91 million -6.6%N/A2.4 $127.06 8/15/20242,290,000 shares $338.39 million -14.2%N/A2.9 $147.77 Get the Latest News and Ratings for NBIX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. 7/31/20242,670,000 shares $377.99 million +1.5%N/A3.4 $141.57 7/15/20242,630,000 shares $387.82 million -6.7%N/A3.4 $147.46 6/30/20242,820,000 shares $388.23 million +26.5%N/A3.6 $137.67 6/15/20242,230,000 shares $302.05 million +4.7%N/A2.8 $135.45 5/31/20242,130,000 shares $288.42 million +14.5%N/A2.6 $135.41 5/15/20241,860,000 shares $264.12 million +1.6%N/A2.2 $142.00 4/30/20241,830,000 shares $251.70 million -9.4%N/A2.1 $137.54 4/15/20242,020,000 shares $266.11 million -16.9%N/A2.3 $131.74 3/31/20242,430,000 shares $335.15 million -2.0%N/A2.8 $137.92 3/15/20242,480,000 shares $344.97 million +13.8%N/A2.9 $139.10 2/29/20242,180,000 shares $284.27 million No ChangeN/A2.6 $130.40 2/15/20242,180,000 shares $292.12 million +16.0%N/A2.7 $134.00 1/31/20241,880,000 shares $262.77 million -18.6%N/A2.4 $139.77 1/15/20242,310,000 shares $304.99 million +1.8%N/A3.1 $132.03 12/31/20232,270,000 shares $299.10 million -0.4%N/A3.2 $131.76 12/15/20232,280,000 shares $274.10 million +8.1%N/A3.2 $120.22 11/30/20232,110,000 shares $246.00 million -7.5%N/A3.1 $116.59 11/15/20232,280,000 shares $252.42 million +2.2%N/A3.4 $110.71 10/31/20232,230,000 shares $247.40 million +1.8%N/A3.4 $110.94 10/15/20232,190,000 shares $247.12 million +18.4%N/A3.2 $112.84 9/30/20231,850,000 shares $208.13 million -8.4%N/A2.6 $112.50 9/15/20232,020,000 shares $227.15 million No ChangeN/A2.8 $112.45 8/31/20232,020,000 shares $219.96 million +3.6%N/A2.6 $108.89 8/15/20231,950,000 shares $207.32 million -3.9%N/A2.6 $106.32 7/31/20232,030,000 shares $206.84 million -12.9%N/A2.7 $101.89 7/15/20232,330,000 shares $221.61 million -3.7%N/A3.1 $95.11 6/30/20232,420,000 shares $228.21 million -5.1%N/A3.3 $94.30 6/15/20232,550,000 shares $246.97 million -1.9%N/A3.5 $96.85 5/31/20232,600,000 shares $232.78 million -6.8%N/A3.7 $89.53 5/15/20232,790,000 shares $273.84 million +5.7%N/A4 $98.15 4/30/20232,640,000 shares $266.75 million +3.5%N/A3.5 $101.04 4/15/20232,550,000 shares $262.09 million -7.6%N/A3.4 $102.78 3/31/20232,760,000 shares $279.37 million +3.4%N/A3.4 $101.22 3/15/20232,670,000 shares $251.27 million +5.1%N/A3.4 $94.11The centerpiece of Trump’s crypto’s masterplan … (Ad)Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”Click here to find out more about what could be Trump and JD Vance’s favorite coin. 2/28/20232,540,000 shares $261.87 million -1.6%N/A3.2 $103.10 2/15/20232,580,000 shares $267.62 million -1.2%N/A3.3 $103.73 1/31/20232,610,000 shares $289.53 million +0.8%2.8%3.2 $110.93 1/15/20232,590,000 shares $282.28 million +15.1%2.8%3.2 $108.99 12/30/20222,250,000 shares $268.74 million +0.5%2.4%2.8 $119.44 12/15/20222,240,000 shares $261.39 million -16.7%2.4%2.7 $116.69 11/30/20222,690,000 shares $341.79 million -5.3%2.9%3.3 $127.06 11/15/20222,840,000 shares $325.95 million +8.0%3.0%3.5 $114.77 10/31/20222,630,000 shares $302.77 million -4.0%2.8%3.3 $115.12 10/15/20222,740,000 shares $296.55 million +3.0%2.9%3.6 $108.23 9/30/20222,660,000 shares $282.52 million +10.4%2.8%3.6 $106.21 9/15/20222,410,000 shares $257.70 million +11.6%2.6%3.4 $106.93 8/31/20222,160,000 shares $226.00 million -21.7%2.3%3 $104.63 8/15/20222,760,000 shares $296.40 million +7.0%3.0%3.7 $107.39 7/31/20222,580,000 shares $242.86 million -0.8%2.8%3.3 $94.13 7/15/20222,600,000 shares $247.44 million +5.3%2.8%3.4 $95.17 6/30/20222,470,000 shares $240.78 million -33.8%2.6%3.2 $97.48 6/15/20223,730,000 shares $347.45 million +4.2%4.2%5 $93.15 5/31/20223,580,000 shares $334.69 million -17.1%3.8%4.9 $93.49 5/15/20224,320,000 shares $363.40 million +23.1%4.6%6.1 $84.12 4/30/20223,510,000 shares $316.01 million +7.7%3.8%4.6 $90.03 4/15/20223,260,000 shares $323.62 million +9.8%3.5%4.4 $99.27 3/31/20222,970,000 shares $278.44 million +1.0%3.2%3.5 $93.75 3/15/20222,940,000 shares $267.72 million +2.4%3.2%3.5 $91.06 2/28/20222,870,000 shares $257.93 million +3.2%3.1%3.2 $89.87 2/15/20222,780,000 shares $240.44 million -2.5%3.0%3 $86.49 1/31/20222,850,000 shares $225.21 million +13.1%3.1%3.2 $79.02 1/15/20222,520,000 shares $197.47 million -10.6%2.7%2.8 $78.36 12/31/20212,820,000 shares $240.18 million -4.7%3.1%3.4 $85.17 12/15/20212,960,000 shares $250.59 million +8.4%3.2%3.8 $84.66 11/30/20212,730,000 shares $227.27 million -13.9%3.0%3.7 $83.25 11/15/20213,170,000 shares $278.26 million -14.1%3.4%5 $87.78 10/29/20213,690,000 shares $388.96 million +2.2%4.0%5.9 $105.41 10/15/20213,610,000 shares $377.39 million +4.3%3.9%5.9 $104.54 9/30/20213,460,000 shares $331.85 million -0.9%3.8%5.6 $95.91 9/15/20213,490,000 shares $336.23 million -6.7%3.8%5.3 $96.34 8/31/20213,740,000 shares $356.05 million +4.8%4.1%5.6 $95.20 8/13/20213,570,000 shares $318.16 million -13.6%3.9%4.8 $89.12 7/30/20214,130,000 shares $384.96 million +3.0%4.5%5.5 $93.21 7/15/20214,010,000 shares $376.06 million -8.5%4.3%5.6 $93.78 6/30/20214,380,000 shares $426.26 million -1.1%4.7%6 $97.32 6/15/20214,430,000 shares $433.65 million -13.5%4.8%4.1 $97.89 5/28/20215,120,000 shares $492.65 million -3.8%5.5%4.7 $96.22 5/14/20215,320,000 shares $489.07 million -11.6%N/A4.7 $91.93 4/30/20216,020,000 shares $573.89 million -3.2%N/A5.1 $95.33 4/15/20216,220,000 shares $591.21 million -11.1%N/A5.3 $95.05 3/31/20217,000,000 shares $659.82 million +57.3%N/A5.6 $94.26 3/15/20214,450,000 shares $431.92 million +18.7%N/A5.1 $97.06 2/26/20213,750,000 shares $400.54 million -7.4%N/A4.2 $106.81 2/12/20214,050,000 shares $467.41 million -1.2%N/A4.5 $115.41How one pattern has averaged an 85% return per year since the pandemic. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… 1/29/20214,100,000 shares $458.91 million -6.2%N/A4.1 $111.93 1/15/20214,370,000 shares $477.60 million No ChangeN/A4.5 $109.29 12/31/20204,370,000 shares $417.16 million +1.4%N/A4.8 $95.46 12/15/20204,310,000 shares $402.81 million -7.9%N/A4.7 $93.46 11/30/20204,680,000 shares $447.22 million -3.1%N/A4.9 $95.56 11/15/20204,830,000 shares $444.26 million -5.7%N/A5.1 $91.98 10/30/20205,120,000 shares $506.47 million +1.8%N/A6.1 $98.92 10/15/20205,030,000 shares $508.18 million -2.1%N/A6.4 $101.03 9/30/20205,140,000 shares $494.26 million -9.4%N/A6.4 $96.16 9/15/20205,670,000 shares $591.38 million +3.5%N/A7.1 $104.30 8/31/20205,480,000 shares $637.98 million +3.6%N/A7 $116.42 8/14/20205,290,000 shares $605.12 million -6.2%N/A6.7 $114.39 7/31/20205,640,000 shares $678.83 million +12.6%N/A6.5 $120.36 7/15/20205,010,000 shares $656.91 million +3.9%N/A5.8 $131.12 6/30/20204,820,000 shares $604.91 million +4.1%N/A5.6 $125.50 6/15/20204,630,000 shares $533.98 million -1.9%N/A5.5 $115.33 5/29/20204,720,000 shares $588.87 million -2.3%N/A5.3 $124.76 5/15/20204,830,000 shares $562.70 million -5.1%N/A5.4 $116.50 4/30/20205,090,000 shares $499.53 million -2.7%N/A6.3 $98.14 4/15/20205,230,000 shares $497.53 million +3.0%N/A6.5 $95.13 3/31/20205,080,000 shares $498.75 million -1.0%5.6%6.1 $98.18 3/13/20205,133,100 shares $496.27 million +4.1%5.6%6.6 $96.68 2/28/20204,930,000 shares $389.52 million +13.6%5.4%6 $79.01 2/14/20204,340,000 shares $400.32 million +2.1%4.8%4.9 $92.24 1/31/20204,250,000 shares $399.29 million +3.2%4.7%4.5 $93.95 1/15/20204,120,000 shares $440.72 million -2.8%4.5%4.4 $106.97 12/31/20194,240,000 shares $420.48 million -8.4%4.7%4.5 $99.17 NBIX Short Interest - Frequently Asked Questions What is Neurocrine Biosciences' current short interest? Short interest is the volume of Neurocrine Biosciences shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 2,480,000 shares of NBIX short. Learn More on Neurocrine Biosciences' current short interest. What is a good short interest ratio for Neurocrine Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBIX shares currently have a short interest ratio of 3.0. Learn More on Neurocrine Biosciences's short interest ratio. Which institutional investors are shorting Neurocrine Biosciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Neurocrine Biosciences: Jane Street Group LLC, Wolverine Trading LLC, Walleye Trading LLC, Walleye Capital LLC, PEAK6 Investments LLC, Citigroup Inc., LMR Partners LLP, Genus Capital Management Inc., and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Neurocrine Biosciences' short interest increasing or decreasing? Neurocrine Biosciences saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 2,480,000 shares, a decrease of 5.3% from the previous total of 2,620,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Neurocrine Biosciences' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Neurocrine Biosciences: Bio-Techne Co. (2.00%), Qiagen (1.61%), CRISPR Therapeutics AG (21.78%), Denali Therapeutics Inc. (5.93%), Adaptive Biotechnologies Co. (6.07%), Alnylam Pharmaceuticals, Inc. (2.87%), Biogen Inc. (2.16%), United Therapeutics Co. (5.24%), Incyte Co. (3.90%), BioMarin Pharmaceutical Inc. (2.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Neurocrine Biosciences stock? Short selling NBIX is an investing strategy that aims to generate trading profit from Neurocrine Biosciences as its price is falling. NBIX shares are trading down $5.44 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Neurocrine Biosciences? A short squeeze for Neurocrine Biosciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NBIX, which in turn drives the price of the stock up even further. How often is Neurocrine Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBIX, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies TECH Short Interest QGEN Short Interest CRSP Short Interest DNLI Short Interest ADPT Short Interest ALNY Short Interest BIIB Short Interest UTHR Short Interest INCY Short Interest BMRN Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NBIX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
